Given the high prevalence of NRF2 hyperactivation in KEAP1-mutant NSCLC—and its established links to immune escape and drug resistance—KEAP1/NRF2 genetic background emerges as a clinically relevant biomarker to stratify patients for SH003-based therapeutic strategies [44,45,46,47]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.